<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We are conducting an open-label multicentre phase II study to evaluate the efficacy and safety of the combination therapy of XELOX and bevacizumab in late-stage elderly patients with unresectable advanced/<z:e sem="disease" ids="C0854750" disease_type="Neoplastic Process" abbrv="">recurrent colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The primary endpoint of the study is progression-free survival </plain></SENT>
<SENT sid="2" pm="."><plain>The secondary endpoints are the toxicity, overall response rate, time to treatment failure and overall survival </plain></SENT>
<SENT sid="3" pm="."><plain>Thirty-five patients are required for the study </plain></SENT>
</text></document>